Podcast: James Lanthier – Patentability, Capitalism, and The Next Generation of Psychedelics

Podcast: James Lanthier – Patentability, Capitalism, and The Next Generation of Psychedelics
CANNANNEW REPORT

JUNE 28, 2022 BY PSYCHEDELICS TODAY PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation of Psychedelics Psychedelics Today         LISTEN AT https://psychedelicstoday.com/2022/06/28/pt332/?ck_subscriber_id=1050193520 In this episode of the podcast, Joe interviews the CEO of Mindset Pharma, James Lanthier. Mindset Pharma is a 3-year old biotechnology company built on discovering and developing new psychedelic compounds to be used as medicine for a variety of indications. While the efficacy of the psychedelics we know can’t be denied, the goal of science is to improve, and Lanthier believes optimizing these drugs will make them safer, more predictable, and more palatable for a far greater portion of the population. He envisions these new molecules leading to a future of highly personalized medicine, where people who would never eat a mushroom would likely take a related drug prescribed by their doctor. Lanthier discusses what’s going on at Mindset Pharma; why patents alone will not be sufficient protection from competition; the long game of biotech, psychedelic stocks, and overreaction to slow growth; the Nagoya protocol; mescaline; the need for big pharma and capitalism; the art of formulation; and how microdosing could soon be revolutionized. Notable Quotes “I had some fairly well-known psychedelic investors say to me, ‘You’re just building a better mousetrap.’ And my reaction was: ‘Well, that’s the march of science. That’s what science is trying to do.’ Take the example of what the German scientist [Felix Hoffman] did in the nineteenth century to go from the bark of the willow tree, eventually going through a whole bunch of intermediate chemical steps to eventually get to Aspirin. Science hopefully tries to make things better, and that’s what we’re trying to do.” “Big pharma has skipped right past psilocybin. Why? In my view, it would be because of the lack of strong IP rights. They’ve gone right…

Excerpt only …
READ MORE BELOW
Source : Podcast: James Lanthier – Patentability, Capitalism, and The Next Generation of Psychedelics

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.